<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>391</serviceExecutionTime><Drug id="79391"><DrugName>rituximab biosimilar, Sandoz</DrugName><DrugNamesKey><Name id="43100527">Rixathon</Name><Name id="43100528">Riximyo</Name><Name id="42758398">rituximab</Name></DrugNamesKey><DrugSynonyms><Name><Value>rituximab</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>rituximab biosimilar, Sandoz</Value></Name><Name><Value>GP-2013</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Rixathon</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Riximyo</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Rituximab BS</Value></Name></DrugSynonyms><CompanyOriginator id="1017404">Sandoz International GmbH</CompanyOriginator><CompaniesPrimary><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Company id="1017404">Sandoz International GmbH</Company></CompaniesPrimary><CrossReferences><SourceEntity id="79391" type="Drug"><TargetEntity id="719390" type="siDrug">Rituximab</TargetEntity><TargetEntity id="725557" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1017404" type="Company"><TargetEntity id="5000072957" type="organizationId">Sandoz International GmbH</TargetEntity></SourceEntity><SourceEntity id="1042596" type="Company"><TargetEntity id="4295877429" type="organizationId">Kyowa Kirin Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1532" type="ciIndication"><TargetEntity id="10047115" type="MEDDRA"/><TargetEntity id="D014657" type="MeSH"/><TargetEntity id="-865701041" type="omicsDisease"/><TargetEntity id="1201" type="siCondition"/></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"/><TargetEntity id="D008224" type="MeSH"/><TargetEntity id="-1402578461" type="omicsDisease"/><TargetEntity id="1742" type="siCondition"/></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"/><TargetEntity id="10012818" type="MEDDRA"/><TargetEntity id="D016403" type="MeSH"/><TargetEntity id="544" type="ORPHANET"/><TargetEntity id="-308083648" type="omicsDisease"/><TargetEntity id="1741" type="siCondition"/></SourceEntity><SourceEntity id="1888" type="ciIndication"><TargetEntity id="M31.3" type="ICD10"/><TargetEntity id="10047888" type="MEDDRA"/><TargetEntity id="D014890" type="MeSH"/><TargetEntity id="900" type="ORPHANET"/><TargetEntity id="-303927819" type="omicsDisease"/><TargetEntity id="736" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00379" type="ciTarget"><TargetEntity id="4436248919313" type="siTarget">B-lymphocyte antigen CD20</TargetEntity><TargetEntity id="-827076151" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Chronic lymphocytic leukemia - EU - Jul-2017</FirstLaunched><FirstLaunched>Chronic lymphocytic leukemia - Germany - Jul-2017</FirstLaunched><FirstLaunched>Chronic lymphocytic leukemia - UK - Jul-2017</FirstLaunched><FirstLaunched>Diffuse large B-cell lymphoma - EU - Jul-2017</FirstLaunched><FirstLaunched>Diffuse large B-cell lymphoma - Germany - Jul-2017</FirstLaunched><FirstLaunched>Diffuse large B-cell lymphoma - UK - Jul-2017</FirstLaunched><FirstLaunched>Follicle center lymphoma - EU - Jul-2017</FirstLaunched><FirstLaunched>Follicle center lymphoma - Germany - Jul-2017</FirstLaunched><FirstLaunched>Follicle center lymphoma - UK - Jul-2017</FirstLaunched><FirstLaunched>Non-Hodgkin lymphoma - EU - Jul-2017</FirstLaunched><FirstLaunched>Non-Hodgkin lymphoma - Germany - Jul-2017</FirstLaunched><FirstLaunched>Non-Hodgkin lymphoma - UK - Jul-2017</FirstLaunched><FirstLaunched>Rheumatoid arthritis - EU - Jul-2017</FirstLaunched><FirstLaunched>Rheumatoid arthritis - Germany - Jul-2017</FirstLaunched><FirstLaunched>Rheumatoid arthritis - UK - Jul-2017</FirstLaunched><FirstLaunched>Vasculitis - EU - Jul-2017</FirstLaunched><FirstLaunched>Vasculitis - Germany - Jul-2017</FirstLaunched><FirstLaunched>Vasculitis - UK - Jul-2017</FirstLaunched><FirstLaunched>Wegener granulomatosis - EU - Jul-2017</FirstLaunched><FirstLaunched>Wegener granulomatosis - Germany - Jul-2017</FirstLaunched><FirstLaunched>Wegener granulomatosis - UK - Jul-2017</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1532">Vasculitis</Indication><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="1888">Wegener granulomatosis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="962">Biosimilar product</Technology></Technologies><LastModificationDate>2019-07-02T11:31:50.000Z</LastModificationDate><ChangeDateLast>2019-07-03T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1017404" linkType="Company"&gt;Sandoz&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;), has developed and launched GP-2013 (Rixathon; Riximyo; Rituximab BS) , a biosimilar version of the murine/human chimeric anti-CD20 monoclonal antibody &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;, for the iv treatment of rheumatoid arthritis (RA), non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL),  chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (Wegener's granulomatosis), and microscopic polyangiitis  [&lt;ulink linkID="1270058" linkType="Reference"&gt;1270058&lt;/ulink&gt;], [&lt;ulink linkID="1308551" linkType="Reference"&gt;1308551&lt;/ulink&gt;], [&lt;ulink linkID="1920844" linkType="Reference"&gt;1920844&lt;/ulink&gt;], [&lt;ulink linkID="1938868" linkType="Reference"&gt;1938868&lt;/ulink&gt;], [&lt;ulink linkID="1998025" linkType="Reference"&gt;1998025&lt;/ulink&gt;].  In June 2017, the EC approved the drug for the same indications as rituximab [&lt;ulink linkID="1938868" linkType="Reference"&gt;1938868&lt;/ulink&gt;]; by July 2017, launch had begun in certain European countries, beginning in the UK and Germany [&lt;ulink linkID="1945748" linkType="Reference"&gt;1945748&lt;/ulink&gt;]. By November 2018, the biosimilar had been approved in Switzerland and Australia [&lt;ulink linkID="2090080" linkType="Reference"&gt;2090080&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In January 2018, the drug was launched in Japan by &lt;ulink linkID="1042596" linkType="Company"&gt;Kyowa Hakko Kirin&lt;/ulink&gt; for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disease under immunosuppression, Wegener's granulomatosis and microscopic polyangiitis [&lt;ulink linkID="1998025" linkType="Reference"&gt;1998025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, the drug was in phase III trials for FL [&lt;ulink linkID="1308551" linkType="Reference"&gt;1308551&lt;/ulink&gt;]. In January 2014, the drug was in phase III trials for NHL including FL, Wegener's granulomatosis, and microscopic polyangiitis [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]. In July 2015, a phase III study for RA was initiated [&lt;ulink linkID="1684877" linkType="Reference"&gt;1684877&lt;/ulink&gt;]; recruitment completed in March 2016 [&lt;ulink linkID="1753852" linkType="Reference"&gt;1753852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, the US FDA accepted the BLA [&lt;ulink linkID="1961042" linkType="Reference"&gt;1961042&lt;/ulink&gt;]; in May 2018,  the US FDA issued a  complete response letter (CRL) [&lt;ulink linkID="2030175" linkType="Reference"&gt;2030175&lt;/ulink&gt;]; in November 2018, the company decided not to pursueÂ submission of BLA  following the request of additional information  by the FDA, and further development in the US  was presumed to be discontinued   at this time [&lt;ulink linkID="2090080" linkType="Reference"&gt;2090080&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2017, the US FDA accepted the BLA filed by the company for the approval of the drug for blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis [&lt;ulink linkID="1961042" linkType="Reference"&gt;1961042&lt;/ulink&gt;]. In May 2018, the US FDA issued a CRL	[&lt;ulink linkID="2030175" linkType="Reference"&gt;2030175&lt;/ulink&gt;]. In November 2018, the company decided not to pursueÂ submission of BLA  following the request of additional information  by the FDA  [&lt;ulink linkID="2090080" linkType="Reference"&gt;2090080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In May 2016, the EMA   accepted an MAA  for the treatment of all indications included in the reference product's  (rituximab) label, including NHL including FL and DLBCL, CLL and RA [&lt;ulink linkID="1765287" linkType="Reference"&gt;1765287&lt;/ulink&gt;]. In April 2017, the   CHMP had adopted positive opinions and  separately recommending the approval of     rituximab  biosimilar in Europe [&lt;ulink linkID="1919949" linkType="Reference"&gt;1919949&lt;/ulink&gt;]. In June 2017, the EC approved the drug for NHL including FL and DLBCL, CLL, and immunological diseases such as rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis [&lt;ulink linkID="1938868" linkType="Reference"&gt;1938868&lt;/ulink&gt;]; by July 2017, launch had begun in certain European countries, beginning in the UK and Germany [&lt;ulink linkID="1945748" linkType="Reference"&gt;1945748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2018, the biosimilar had been approved in Switzerland [&lt;ulink linkID="2090080" linkType="Reference"&gt;2090080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In November 2016, Sandoz filed a marketing application in Japan and the drug would be marketed by Kyowa Hakko Kirin after drug was approved [&lt;ulink linkID="1870353" linkType="Reference"&gt;1870353&lt;/ulink&gt;]. In January 2018, the drug was launched in Japan by Kyowa Hakko Kirin for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disease under immunosuppression, Wegener's granulomatosis and microscopic polyangiitis [&lt;ulink linkID="1998025" linkType="Reference"&gt;1998025&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the worldAsia Pacific&lt;/subtitle&gt;By November 2018, the biosimilar had been approved in Australia  [&lt;ulink linkID="2090080" linkType="Reference"&gt;2090080&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In July 2015, a phase III randomized, double- blind, controlled, parallel-group, multicenter study (&lt;ulink linkID="236554" linkType="Protocol"&gt;NCT02514772&lt;/ulink&gt;; ASSIST-RT; GP13-302) to assess the safety and immunogenicity of transitioning to GP-2013 or re-treatment with Rituxan or MabThera was initiated in patients (expected n = 100) with active RA, previously treated with Rituxan or MabThera, in the US. At that time, the study was expected to complete in July 2017. By December 2015, the  trial was also recruiting in Europe [&lt;ulink linkID="1684877" linkType="Reference"&gt;1684877&lt;/ulink&gt;]. Recruitment completed in March 2016 [&lt;ulink linkID="1753852" linkType="Reference"&gt;1753852&lt;/ulink&gt;]. In November 2016, the company applied for marketing and manufacturing approval of the drug and based on the license agreement signed on January 26, 2016, GP-2013 will be marketed by &lt;ulink linkID="1042596" linkType="Company"&gt;Kyowa Hakko Kirin&lt;/ulink&gt; after approved  [&lt;ulink linkID="1870353" linkType="Reference"&gt;1870353&lt;/ulink&gt;]. In November 2017, further clinical data from 107 patients were presented at the 81st ACR Annual Meeting in San Diego, CA. In switch and control groups, most of the patients (94.3 and 96.3%, respectively) completed the study up to 24 weeks. In switch versus control groups, the incidence of hypersensitivity was observed in 9.4 versus 11.1% of patients, respectively; infusion-related reactions were reported in 11.3 versus 18.5% of patients, respectively; anaphylactic reactions were reported in 0 and 1.9% of patients, respectively; and antidrug antibody positive after screening was observed in 0 and 2.1% of patients, respectively [&lt;ulink linkID="1978373" linkType="Reference"&gt;1978373&lt;/ulink&gt;], [&lt;ulink linkID="1981719" linkType="Reference"&gt;1981719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, the drug was in phase III trials for Wegener's granulomatosis, NHL and microscopic polyangiitis  [&lt;ulink linkID="1519399" linkType="Reference"&gt;1519399&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2011, a randomized, controlled, double-blind, phase III trial (&lt;ulink linkID="89501" linkType="Protocol"&gt;NCT01419665&lt;/ulink&gt;; GP13-301, 2010-019522-13; ASSIST-FL) began in  Australia, South America, Europe, India, Israel, Japan, South Africa and Malaysia to compare the efficacy, safety and pharmacokinetics of GP-2013 versus &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; in patients (expected n = 618) with previously untreated, advanced stage FL. At that time, completion was expected in October 2013 [&lt;ulink linkID="1308551" linkType="Reference"&gt;1308551&lt;/ulink&gt;]. In January 2015, recruitment was completed [&lt;ulink linkID="1629087" linkType="Reference"&gt;1629087&lt;/ulink&gt;]. In December 2016, results were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Patients (n = 629) were randomized to receive GP-2013 (375 mg/m2) + cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) + prednisone (100 mg, po; GP2013-CVP group; n = 314) or rituximab (375 mg/m2) + cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) + prednisone (100 mg, po; R-CVP group; n = 315). Patients (n = 629) were randomized to receive GP-2013 (375 mg/m2) + cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) + prednisone (100 mg, po; GP2013-CVP group; n = 314) or rituximab (375 mg/m2) + cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2) + prednisone (100 mg, po; R-CVP group; n = 315). Best overall response for complete response (14.8 and 13.4%, respectively) and partial response (72.3 and 74.1%, respectively) was comparable between GP-2013-CVP and R-CVP in the combination phase. GP-2013 appeared to be safe as rituximab [&lt;ulink linkID="1881309" linkType="Reference"&gt;1881309&lt;/ulink&gt;], [&lt;ulink linkID="1881978" linkType="Reference"&gt;1881978&lt;/ulink&gt;]. In July 2017, similar data were published [&lt;ulink linkID="1881978" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1957573" linkType="Reference"&gt;1957573&lt;/ulink&gt;], [&lt;ulink linkID="1957326" linkType="Reference"&gt;1957326&lt;/ulink&gt;]. In September 2017, further clinical data were presented at ESMO 2017 Congress in Madrid, Spain. The equivalence of overall response rate between GP-2013- cyclophosphamide, vincristine, and prednisone and rituximab- cyclophosphamide, vincristine, and prednisone, was met (87.1 and 87.5%, respectively) (primary endpoint) and was similar between both the arms regardless of age (&amp;lt;, &amp;gt;/= 60 years), gender, race, geographic region or bulky disease [&lt;ulink linkID="1960532" linkType="Reference"&gt;1960532&lt;/ulink&gt;]. In September 2017, data were presented at ESMO 2017 Congress in Madrid, Spain. As of 31 Dec 2016, in patients treated with GP-2013 or rituximab maintenance, median follow-up was 23.6 and 24.2 months, respectively; high level of censoring without progression free survival (PFS) or overall survival (OS), for time-dependent endpoints were 70 and 90% events; hazard ratio for PFS and OS were 1.31 and 0.77, respectively [1960702]. In September 2017, data were presented at ESMO 2017 Congress in Madrid, Spain. As of 31 Dec 2016, in patients treated with GP-2013 or rituximab maintenance, median follow-up was 23.6 and 24.2 months, respectively; high level of censoring without progression free survival (PFS) or overall survival (OS), for time-dependent endpoints were 70 and 90% events; hazard ratio for equivalence PFS and OS were 1.31 and 0.77, respectively [&lt;ulink linkID="1960702" linkType="Reference"&gt;1960702&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2011, a randomized, double-blind, controlled, phase I/II trial (&lt;ulink linkID="89502" linkType="Protocol"&gt;NCT01274182&lt;/ulink&gt;; GP13-201; 2010-021184-32; GPN013A2301; ASSIST-RA) was initiated in  Europe, South America and India to evaluate the pharmacokinetics, pharmacodynamics, safety and efficacy of GP-2013 (1000 mg) compared with rituximab (1000 mg) via  iv infusion in patients (expected n = 164) with severe RA refractory or intolerant to standard antirheumatic drugs   and one or two anti-TNF therapies. At that time, the  study was not yet recruiting in Argentina, Brazil,  Italy and Turkey and the trial was expected to complete in April 2012 [&lt;ulink linkID="1270058" linkType="Reference"&gt;1270058&lt;/ulink&gt;]; in May 2014, the trial was ongoing [&lt;ulink linkID="1552907" linkType="Reference"&gt;1552907&lt;/ulink&gt;]. Recruitment completed in June 2015 [&lt;ulink linkID="1753852" linkType="Reference"&gt;1753852&lt;/ulink&gt;]. In June 2016, first clinical data were presented from 173 randomized rheumatoid arthritis patients, at the 17th EULAR Annual European Congress of Rheumatology in London, UK. From baseline to week 24, a non-inferiority of disease activity score (DAS)28 change was seen with GP-2013 showing a LS Mean reduction of -2.16 compared with -2.23 for rituximab. There was one death in the GP-2013 group; however, this was not considered to be treatment related. Other non-fatal serious adverse events were seen in 10 and 14 subjects receiving GP-2013 and rituximab, respectively, with 2 and 4 of these leading to discontinuation. The most common adverse events included infections and infestations, musculoskeletal, gastrointestinal, general, and skin and subcutaneous tissue disorders [&lt;ulink linkID="1767893" linkType="Reference"&gt;1767893&lt;/ulink&gt;], [&lt;ulink linkID="1773182" linkType="Reference"&gt;1773182&lt;/ulink&gt;], [&lt;ulink linkID="1771152" linkType="Reference"&gt;1771152&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In June 2019, interim analysis results from the prospective, non-interventional, observational, multicenter, open-label study (REFLECT) of biosimilar rituximab administered in combination with CHOP chemotherapy in treatment-naive patients with CD20+ DLBCL (n = 80) were presented at the 24th EHA Annual Congress in Amsterdam, Netherlands. Overall, adverse events (AEs) were reported in 53 patients. Polyneuropathy, anemia, and fatigue were the most frequently reported AEs. A total of 23 treatment-related AEs were reported in 13 patients; of which, 10 events were blood and lymphatic system disorders. Serious AEs were reported in 19 patients; two were treatment-related. Deaths were not reported. At that time, recruitment was completed in March 2019 and data collection was ongoing [&lt;ulink linkID="2164684" linkType="Reference"&gt;2164684&lt;/ulink&gt;] &lt;/para&gt;&lt;para&gt;In  November 2017, data from a randomized, double-blind study which evaluated the efficacy and bioequivalence of GP-2013 compared with rituximab-EU and rituximab-US in patients (n = 312) with rheumatoid arthritis were presented at the 81st ACR Annual Meeting in San Diego, CA. Patients were randomized to receive GP-2013, rituximab-EU or rituximab-US.Â In GP-2013, rituximab-US, and rituximab-EU groups, adjusted geometric mean values of AUC (0 to infinity) (primary endpoint) were 7627.44, 7536.89, and 6896.97 day.microg/ml, respectively; Cmax (key secondary endpoint) was 361.53, 335.88, and 319.80 microg/ml, respectively; AUEC (0 to 14 days) (key secondary pharmacodynamic endpoint) was 1226.53, 1240.57, and 1201.15%.day, respectively, at week 24. Additionally, GP-2013 and rituximab were similar in terms of efficacy, safety and immunogenicity up to week 52 [&lt;ulink linkID="1978235" linkType="Reference"&gt;1978235&lt;/ulink&gt;], [&lt;ulink linkID="1981719" linkType="Reference"&gt;1981719&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2013, preclinical data were presented at the 49th ASCO meeting in Chicago, IL.Â In cynomolgus monkeys, the mean concentration-time profiles of GP-2013 and originator rituximab were similar over first 9 days post-administration. GP-2013 and originator rituximab were comparable with nearly identical AUCs and 90% clearance [&lt;ulink linkID="1425608" linkType="Reference"&gt;1425608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, preclinical data were presented at the ACR/ARHP Annual Meeting in Washington DC. Similar antibody-dependent cellular cytotoxicity potency against SU-DHL-4 and Daudi cells were seen with rituximab and GP-2013. In  SCID mouse models of non-Hodgkin's lymphoma, GP-2013 and rituximab showed similar tumor growth inhibition. In cynomolgus monkeys, PK analysis confirmed bioequivalence between GP-2013 and rituximab. Bioequivalence of PD response (B-cell depletion) was also shown. Different dose studies also showed comparable exposure and PD response for GP-2013 and rituximab [&lt;ulink linkID="1343317" linkType="Reference"&gt;1343317&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-01-18T00:00:00.000Z</StatusDate><Source id="1998025" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2018-01-18T00:00:00.000Z</StatusDate><Source id="1998025" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2018-01-18T00:00:00.000Z</StatusDate><Source id="1998025" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-01-18T00:00:00.000Z</StatusDate><Source id="1998025" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-07-18T00:00:00.000Z</StatusDate><Source id="1945748" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="MY">Malaysia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2018-11-02T00:00:00.000Z</StatusDate><Source id="2090080" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1017404">Sandoz International GmbH</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-01-10T00:00:00.000Z</StatusDate><Source id="1270058" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2014-01-29T00:00:00.000Z</StatusDate><Source id="1519399" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2014-01-29T00:00:00.000Z</StatusDate><Source id="1519399" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2014-01-29T00:00:00.000Z</StatusDate><Source id="1519399" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2015-12-04T00:00:00.000Z</StatusDate><Source id="1684877" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2016-05-24T00:00:00.000Z</StatusDate><Source id="1765287" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1532">Vasculitis</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1888">Wegener granulomatosis</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2017-06-19T00:00:00.000Z</StatusDate><Source id="1938868" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2016-11-04T00:00:00.000Z</StatusDate><Source id="1870353" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-01-25T00:00:00.000Z</StatusDate><Source id="1729309" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-01-10T00:00:00.000Z</StatusDate><Source id="1270058" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-01-10T00:00:00.000Z</StatusDate><Source id="1270058" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2011-12-20T00:00:00.000Z</StatusDate><Source id="1308551" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2015-07-31T00:00:00.000Z</StatusDate><Source id="1684877" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2017-09-12T00:00:00.000Z</StatusDate><Source id="1961042" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-09-12T00:00:00.000Z</StatusDate><Source id="1961042" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1017404">Sandoz International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-09-12T00:00:00.000Z</StatusDate><Source id="1961042" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00379"><Name>B-lymphocyte antigen CD20</Name><SwissprotNumbers><Swissprot>P11836</Swissprot><Swissprot>P19437</Swissprot><Swissprot>Q3C2E2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2164258" linkType="reference" linkID="2164258"&gt;2164258&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1037687">Kirin Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="158289" title="Kyowa Hakko Kirin to distribute and promote Sandoz's follicle center lymphoma biosimilar rituximab in Japan"/></Deals><PatentFamilies><PatentFamily id="1287479" number="WO-00172333" title="Methods of therapy for non-Hodgkin's lymphoma using a combination of an antibody to CD20 and interleuking-2"/><PatentFamily id="1335152" number="WO-2012069593" title="Fusion enzymes"/><PatentFamily id="1385049" number="WO-03049694" title="Methods of therapy for non-hodgkin's lymphoma"/><PatentFamily id="1531673" number="WO-2005019466" title="Process for the preparation of recombinant polypeptides"/><PatentFamily id="1585732" number="WO-2005017174" title="Process for the purification of recombinant polypeptides"/><PatentFamily id="277767" number="WO-00027428" title="Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody"/><PatentFamily id="3121212" number="WO-2016012468" title="Production of glycoproteins with mammalian-like N-glycans in filamentous fungi"/><PatentFamily id="572386" number="WO-2006089064" title="Methods for treating lymphomas using a combination of a chemotherapeutic agent and Il-2 and optionally an anti-CD20 antibody"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Oulu" id="1004522"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VTT Technical Research Centre Of Finland" id="1005693"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Glykos Finland Oy" id="1013782"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kirin Holdings Co Ltd" id="1037687"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celltrion Healthcare Co Ltd" id="1105372"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Axcel Management A/S" id="1164243"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OY Medix Biochemica AB" id="18016"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gedeon Richter Ltd" id="19441"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Genmab A/S" id="26469"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>